SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Somatostatin Analog Drugs (PHARMACY)

Drug Requested: (select drug below)

❑ **Bynfezia®** (octreotide) **SQ Injection**	❑ **lanreotide acetate extended release SQ injection 120 mg/0.5 mL**
❑ **Mycapssa®** (octreotide) **Oral Tablet**	❑ **octreotide injection** (generic Sandostatin®)
❑ **Sandostatin® LAR Depot** (octreotide)	❑ **Signifor®** (pasireotide) **SQ Injection**
❑ **Somavert®** (pegvisomant) **Injection**	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight: _____ **Date:** _____

****Somatostatin analog use for cancer treatment is outlined in NCCN guidelines for Neuroendocrine Tumors****

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ **Diagnosis: Acromegaly (Bynfezia, lanreotide, octreoctide, Sandostatin LAR, Somavert*)**

Initial Authorization Approval: 12 months

- ❑ Patient is 18 years of age or older

AND

- ❑ Provider is an endocrinologist or neurosurgeon

AND

- ❑ Patient has undergone pituitary surgery and/or irradiation is contraindicated **(chart notes must be submitted to document diagnosis and surgical history or contraindication to surgery)**

AND

- ❑ Diagnosis confirmed by elevated IGF levels as well as inadequate suppression of growth hormone (GH) levels **(labs must be submitted for documentation)**

AND

- ❑ **For Sandostatin LAR and Somavert:** This medication will not be used in combination with other short-acting somatostatin analogs

AND

- ❑ **For Somavert only:** Medication requires trial and failure of a long acting injectable octreotide product (e.g., Bynfezia, Sandostatin)

❑ **Diagnosis: Acromegaly (Bynfezia, lanreotide, octreoctide, Sandostatin LAR, Somavert*)**

Reauthorization Approval: 12 months

- ❑ No toxicity has been observed while taking the requested medication

AND

- ❑ Response is demonstrated by both of the following **(Chart notes must be submitted for documentation)**
  - ❑ Reduction of GH levels from pre-treatment baseline
  - ❑ Normalization of IGF level

AND

- ❑ **For Sandostatin LAR and Somavert:** The patient has not had to use short-acting somatostatin therapy during treatment

(Continued on next page)

❑ Diagnosis: Acromegaly (Mycapssa)

Initial Authorization Approval: 12 months

- ❑ Patient is 18 years of age or older

AND

- ❑ Provider is an endocrinologist or neurosurgeon

AND

- ❑ Patient has undergone pituitary surgery and/or irradiation is contraindicated **(chart notes must be submitted to document diagnosis and surgical history or contraindication to surgery)**

AND

- ❑ Diagnosis confirmed by elevated IGF levels as well as inadequate suppression of growth hormone (GH) levels **(labs must be submitted for documentation)**

AND

- ❑ Member must be established on an injectable somatostatin analogue for ≥6 months with a stable dose for ≥3 months and has shown a clinical response

AND

- ❑ This medication will not be used in combination with other short-acting somatostatin analogs

AND

- ❑ There must be a documented medical necessity for use of oral capsules over injectable alternatives **(chart notes must be submitted to document contraindication to injectable therapy)**

❑ Diagnosis: Acromegaly (Mycapssa)

Reauthorization Approval: 12 months

- ❑ Member has not had to use short-acting somatostatin therapy during treatment

AND

- ❑ No toxicity has been observed while taking Mycapssa

AND

- ❑ Response is demonstrated by both of the following **(Chart notes must be submitted for documentation)**
  - ❑ Reduction of GH levels from pre-treatment baseline
  - ❑ Normalization of IGF level

(Continued on next page)

❑ **Diagnosis: Carcinoid Syndrome (Bynfezia, octreoctide, Sandostatin LAR)**

Authorization Approval: 3 months

- ❑ Patient has one of the following **(Chart notes must be submitted for documentation)**
  - ❑ Severe diarrhea/flushing episodes (carcinoid syndrome) related to hormone hypersecretion in neuroendocrine tumors
  - ❑ Prophylactic administration prior to induction of anesthesia in an individual with a functional carcinoid tumor
  - ❑ Prophylactic administration perioperatively to a surgical procedure in an individual with a functional carcinoid tumor

❑ **Diagnosis – Diarrhea associated with Vasoactive Intestinal Peptide tumors (VIPomas) (Bynfezia, octreoctide, Sandostatin LAR)**

Authorization Approval: 3 months

- ❑ Patient has profuse watery diarrhea associated with VIPomas **(Chart notes must be submitted for documentation)**

❑ **Diagnosis – Cushing's Disease (Signifor SQ)**

Initial Authorization Approval: 6 months

- ❑ Patient is 18 years of age or older

AND

- ❑ Provider is an endocrinologist or neurosurgeon

AND

- ❑ Patient has diagnosis of Cushing's disease and pituitary surgery is not an option or has not been curative **(chart notes must be submitted to document diagnosis and surgical history or contraindication to surgery)**

AND

- ❑ Patient's baseline 24-hour urinary free cortisol level is greater than 1.5 times the upper limit of normal

(labs must be submitted for documentation)

AND

- ❑ Current baseline labs are attached documenting all of the following: liver function tests, fasting plasma glucose, hemoglobin A1c, thyroid function, baseline ECG, and gallbladder ultrasound

(Continued on next page)

❑ **Diagnosis – Cushing's Disease (Signifor SQ)**
Reauthorization Approval: 12 months

- ❑ Patient's current 24-hour urinary free cortisol level is below the upper limit of normal mean **(labs must be submitted for documentation)**

AND

- ❑ Current labs documenting patient's liver function, fasting plasma glucose and hemoglobin A1c are attached

AND

- ❑ Improvements in blood pressure, triglycerides, low-density lipoprotein cholesterol, weight and health related quality of life have been maintained while on Signifor therapy **(Chart notes must be submitted for documentation)**

❑ **Diagnosis: Other**
Please submit documentation showing medical necessity

Medication being provided by Specialty Pharmacy - PropriumRx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee:** 11/19/2021
REVISED/UPDATED/REFORMATTED: ~~4/1/2021; 6/14/2021; 10/11/2021;10/27/2021; 10/30/2021;~~ **2/29/2024**;